clinical trial · NCT04641143
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Biohaven Pharmaceuticals, Inc.·phase3·completed·n = 456
Obsessive-Compulsive DisorderTroriluzolePlacebo
brief summary
The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
started
Dec 22, 2020
primary completion
Oct 27, 2025
completion
Oct 27, 2025
last updated
Jan 7, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol